KPI-012
Persistent Corneal Epithelial Defects (PCED)
Key Facts
About Kala Pharmaceuticals
Kala Pharmaceuticals is a biotech company that has pivoted from its initial focus on commercial ophthalmology products to a clinical-stage strategy targeting rare diseases of the eye. The company's core technology, the AMPPLIFY mucus-penetrating particle platform, is designed to overcome the natural barriers of the eye to improve drug penetration and efficacy. Its lead asset, KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy, is advancing in clinical trials for PCED, with potential in other severe ocular surface conditions. Kala is a publicly traded company (NASDAQ: KALA) that has undergone significant strategic restructuring to focus on this high-need, orphan disease pipeline.
View full company profileAbout Kala Pharmaceuticals
Kala Pharmaceuticals is a biotech company that has pivoted from its initial focus on commercial ophthalmology products to a clinical-stage strategy targeting rare diseases of the eye. The company's core technology, the AMPPLIFY mucus-penetrating particle platform, is designed to overcome the natural barriers of the eye to improve drug penetration and efficacy. Its lead asset, KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy, is advancing in clinical trials for PCED, with potential in other severe ocular surface conditions. Kala is a publicly traded company (NASDAQ: KALA) that has undergone significant strategic restructuring to focus on this high-need, orphan disease pipeline.
View full company profileAbout Kala Pharmaceuticals
Kala Pharmaceuticals is a biotech company that has pivoted from its initial focus on commercial ophthalmology products to a clinical-stage strategy targeting rare diseases of the eye. The company's core technology, the AMPPLIFY mucus-penetrating particle platform, is designed to overcome the natural barriers of the eye to improve drug penetration and efficacy. Its lead asset, KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy, is advancing in clinical trials for PCED, with potential in other severe ocular surface conditions. Kala is a publicly traded company (NASDAQ: KALA) that has undergone significant strategic restructuring to focus on this high-need, orphan disease pipeline.
View full company profileAbout Kala Pharmaceuticals
Kala Pharmaceuticals is a biotech company that has pivoted from its initial focus on commercial ophthalmology products to a clinical-stage strategy targeting rare diseases of the eye. The company's core technology, the AMPPLIFY mucus-penetrating particle platform, is designed to overcome the natural barriers of the eye to improve drug penetration and efficacy. Its lead asset, KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy, is advancing in clinical trials for PCED, with potential in other severe ocular surface conditions. Kala is a publicly traded company (NASDAQ: KALA) that has undergone significant strategic restructuring to focus on this high-need, orphan disease pipeline.
View full company profile